News
OCGN
1.390
0.00%
0.000
Ocugen’s Earnings Call Highlights Risk-Reward Inflection
TipRanks · 1d ago
Ocugen Inc. Stock Rises 10.4%, Outperforms Market
Dow Jones · 2d ago
Ocugen’s Phase 3 Gene Therapy Trial Targets High-Value Dry AMD Market
TipRanks · 2d ago
Weekly Report: what happened at OCGN last week (0810-0814)?
Weekly Report · 4d ago
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
NASDAQ · 6d ago
Ocugen Inc. Stock Advances 4.6%, Outperforms Market
Dow Jones · 08/11 20:34
Weekly Report: what happened at OCGN last week (0803-0807)?
Weekly Report · 08/10 09:34
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Ocugen (OCGN)
TipRanks · 08/10 08:20
Ocugen: Buy Rating Reaffirmed as Cash Runway Extends to 2028 and Ophthalmology Pipeline Advances; $11 Price Target Maintained
TipRanks · 08/07 20:27
Ocugen: Buy Rating Reaffirmed as Late-Stage OCU410/OCU400 Programs Advance; $10 Price Target Maintained
TipRanks · 08/07 10:45
Press Release: Ocugen Provides Business Update with Second Quarter 2026 Financial Results
Dow Jones · 08/06 11:02
Press Release: Ocugen Provides Business Update -2-
Dow Jones · 08/06 11:02
Weekly Report: what happened at OCGN last week (0727-0731)?
Weekly Report · 08/03 09:34
Earnings Week Ahead: PLTR, AMD, PFE, DIS, SHOP, VTRS, CGC, MCD, ROKU, ABNB, and more
Seeking Alpha · 08/02 12:07
Ocugen to Participate in Upcoming August Investor Conferences
Barchart · 07/31 06:02
Analysts’ Top Healthcare Picks: Pulmonx (LUNG), Ocugen (OCGN)
TipRanks · 07/30 13:20
Ocugen Wins FDA RMAT Designation For OCU410 In Dry AMD- Related Geographic Atrophy
NASDAQ · 07/30 09:25
Ocugen granted RMAT designation for OCU410
TipRanks · 07/29 11:51
FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration
Benzinga · 07/29 11:13
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
Barchart · 07/29 06:01
More
Webull provides a variety of real-time OCGN stock news. You can receive the latest news about Ocugen Inc through multiple platforms. This information may help you make smarter investment decisions.
About OCGN
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.